文献速递眼底病与葡萄膜炎神经眼科

抗视网膜抗体检测的临床价值评估

Clinical Utility of Antiretinal Antibody Testing.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

这项横断面研究将14例无自身免疫性视网膜病变患者的血清以盲法送至CLIA认证实验室检测视网膜抗体,结果显示93%样本呈阳性,特异性仅7%,提示当前多数视网膜抗体检测特异性差,临床解读需谨慎。

要点

  • 无自身免疫性视网膜病变患者中93%检出视网膜抗体,特异性仅7%。
  • 除恢复蛋白外,当前视网膜抗体检测临床相关性有限。
  • 低临床怀疑病例应谨慎解读抗体结果,避免不必要的免疫抑制治疗。

核心结论

  • 无自身免疫性视网膜病变患者中93%检出视网膜抗体,表明当前检测缺乏特异性。
  • 除恢复蛋白外,多数可检测的视网膜抗体在评估疑似自身免疫性视网膜病变时临床相关性有限。
  • 当前视网膜抗体检测(除恢复蛋白外)应谨慎解读,尤其在临床怀疑度低时。
  • 特异性差需引起重视,以防止不必要的全身免疫抑制治疗及其显著眼外不良反应。

研究设计与样本

  • 横断面研究,2019年1月1日至10月1日从Mayo Clinic神经免疫生物样本库招募14例无自身免疫性视网膜病变患者。
  • 血清样本以盲法送至CLIA认证实验室检测,Mayo Clinic神经免疫研究实验室用类似方法独立评估以验证可重复性。

主要发现

  • 该实验室检测特异性为7%(95%CI,0%-34%)。
  • 14份样本中12份(86%)人视网膜免疫组化染色确认阳性。
  • α-烯醇化酶在9份(64%)样本中检出,唯一未检出的视网膜抗体是恢复蛋白。
  • Mayo Clinic实验室以猪视网膜蛋白为底物的Western blot重复了这些非特异性抗体结果。

关键数值与推荐

  • 人视网膜免疫组化确认阳性12/14(86%),α-烯醇化酶阳性9/14(64%),恢复蛋白均阴性。

临床怎么用

  • 对疑似自身免疫性视网膜病变患者,当前视网膜抗体检测(除恢复蛋白外)应谨慎解读。
  • 临床怀疑度低时,不应仅凭视网膜抗体阳性启动全身免疫抑制治疗。
  • 需识别对炎症或自身免疫性视网膜疾病有高预测价值的生物标志物以推进该领域。

局限性

  • 样本量仅14例,来自单中心生物样本库。
  • 研究为横断面设计,未评估抗体检测与临床结局的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The clinical utility of most antiretinal antibodies (retina antibodies) currently available for testing remains unclear and unproven. Despite this, the presence of retinal antibodies is included in current diagnostic autoimmune retinopathy criteria. OBJECTIVE: To evaluate the clinical significance of comprehensive retinal antibody evaluations currently offered in North America. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, 14 patients without autoimmune retinopathy were recruited into the Mayo Clinic Neuroimmunology Biorepository for this study between January 1, 2019, and October 1, 2019. These serum samples without autoimmune retinopathy were sent in masked fashion to a Clinical Laboratory Improvement Amendments-certified laboratory. Using similar methods, the Mayo Clinic Neuroimmunology Research Laboratory independently assessed the same sample to ascertain reproducibility of the findings. MAIN OUTCOMES AND MEASURES: Results of the autoimmune retinopathy and cancer-associated retinopathy panels. RESULTS: Thirteen of 14 (93%; 95% CI, 66%-100%) serum samples tested positive for retinal antibodies, with a median of 5 retinal antibodies (range, 0-8) per patient at the Clinical Laboratory Improvement Amendments-certified laboratory, which provides a specificity of 7% (95% CI, 0%-34%). Confirmatory immunohistochemistry staining in human retina was present in 12 of 14 samples (86%). α-Enolase was found in 9 (64%). The only retinal antibody not present was recoverin. These nonspecific retinal antibody results were replicated at the Mayo Clinic Laboratory on Western blot using pig retina proteins as substrate. CONCLUSIONS AND RELEVANCE: The presence of retinal antibodies in 93% of the patients without autoimmune retinopathy indicates a lack of specificity and that most detectable retinal antibodies have limited clinical relevance in the evaluation of patients for suspected autoimmune retinopathy. Current retinal antibody testing, other than recoverin, should be interpreted with caution, especially for cases of low clinical suspicion. The poor specificity is important to recognize to prevent the potentially unnecessary commencement of systemic immunosuppressants that may result in significant extraocular adverse effects. Identification of biomarkers that have a high predictive value for inflammatory or autoimmune retinal diseases is needed to move the field forward.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chen JJ, McKeon A, Greenwood TM, et al. Clinical Utility of Antiretinal Antibody Testing. JAMA Ophthalmol. 2021. PMID: 33885761. doi:10.1001/jamaophthalmol.2021.0651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。